NRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) denied the Breakthrough Therapy designation (BTD) request for ZYESAMI® (aviptadil) and emphasized its focus on the company's NRX-101 BTD compound for Bipolar Depression associated with Suicidality. The request for BTD was submitted based on the positive finding of a post-hoc subgroup analysis of patients who in addition to Aviptadil or placebo were also treated with Remdesivir and whose respiratory failure due to Critical COVID-19 continued to progress.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.27 USD | +4.14% | +7.89% | -28.70% |
Apr. 18 | NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq | MT |
Apr. 18 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.70% | 32.72M | |
+1.93% | 42.59B | |
+8.15% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+9.36% | 24.81B | |
-24.51% | 18.17B | |
+28.47% | 12.05B | |
-3.21% | 11.7B | |
+6.98% | 11.1B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- NRx Pharmaceuticals, Inc. Provides Update on Breakthrough Therapy Designation Request for ZYESAMI®